The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
Growing patent filings and tier-2 innovators reflect expanding national research base
Presbyopia, the age-related loss of near vision, could soon be treated successfully
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Millions of stroke survivors across the world may soon have a new defense
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
